Effect of nandrolone decanoate and 1-alpha-hydroxy-calciferol on patients with vertebral osteoporotic collapse. A double-blind clinical trial.

Abstract

Eighty-eight postmenopausal women with at least one vertebral collapse were randomly assigned to two groups of 44 patients each. All patients were treated for a period of 12 months with 50 mg of nandrolone decanoate every 3 weeks or 1 microgram of 1-alpha-hydroxy-calciferol daily. Both groups received an identical placebo of the inactive drug. Pain intensity was significantly decreased in the nandrolone group and mobility was improved. Patients treated with vitamin D metabolite had also a beneficial but less obvious clinical result. Bone mineral measurements showed an increase of 5% in the nandrolone decanoate group, but a 2.5% decrease in the vitamin D metabolite group. Biochemical results showed a significant hypercalciuric effect of vitamin D metabolite, while nandrolone decanoate caused a reduction in calcium/creatinine excretion. No difference in serum lipids was found during the annual treatment in both groups. It is concluded that nandrolone decanoate has a beneficial effect in clinical symptoms, bone mineral density and biochemical parameters in patients with established osteoporotic vertebral fractures.

• Authors: G P Lyritis, C Androulakis, B Magiasis, Z Charalambaki, N Tsakalakos
• Journal: Bone and mineral (Bone Miner) Vol. 27 Issue 3 Pg. 209-17 (Dec 1994) ISSN: 0169-6009 [Print] Ireland
• PMID: 7696887 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Hydroxycholecalciferols
• Nandrolone
• Creatinine
• Nandrolone Decanoate
• Calcium
• alfacalcidol

Topics

• Aged
• Bone Density
• Calcium (urine)
• Creatinine (urine)
• Double-Blind Method
• Female
• Humans
• Hydroxycholecalciferols (administration & dosage, therapeutic use)
• Middle Aged
• Nandrolone (administration & dosage, analogs & derivatives, therapeutic use)
• Nandrolone Decanoate
• Osteoporosis, Postmenopausal (complications, drug therapy, physiopathology)
• Pain (drug therapy)
• Spinal Fractures (drug therapy, etiology)